MCM2 was significantly overexpressed in almost all human cancers/subtypes in TCGA and was associated with tumor mutation burden, tumor stage, immune therapy response, immune infiltration, and poor patient prognosis [73]. The gene discussed is MCM2; the disease is neoplasm.